Among these 38 patients, 13 achieved a renewed tumor response (34.2%), with 3 patients even showing a complete response to BRAF ± MEKi rechallenge, which was ongoing in two patients at the time of data-lock. This evidence concerns the gene BRAF and neoplasm.